0001628280-25-048915
SEC filing3D Systems' Q3 2025 revenue fell 19.2% YoY to $91.2M, driven by lower dental materials and Geomagic divestiture, with gross margin contracting to 32.3%.
For the three months ended September 30, 2025, total revenue declined 19.2% year-over-year to $91.2 million, driven by a 28.3% drop in product revenue ($20.7 million) as materials volumes weakened in dental, service bureau, and jewelry markets, coupled with the impact of the Geomagic divestiture. Service revenue edged down 2.6% ($1.0 million) due to the divestiture, but ex-Geomagic, service revenue increased on volume gains. Gross profit fell 29.4% to $29.4 million, with gross margin contracting 460 bps to 32.3%, primarily attributable to the Geomagic divestiture and lower sales volumes. Operating loss narrowed dramatically to $21.3 million from $180.8 million in the prior year, as the prior period included $143.7 million in asset impairment charges. SG&A expenses dropped 40.1% to $34.7 million, reflecting lower compensation, consulting, and amortization costs, partially offset by $1.4 million in restructuring charges. R&D spending decreased 22.8% to $16.0 million, driven by headcount reductions and improved efficiency from restructuring.
Healthcare Solutions revenue fell 22.3% to $42.8 million, led by an $11.6 million decline in materials revenue from lower dental market sales, including reduced volumes with a key customer. Segment gross profit decreased 29.6% to $16.4 million. Industrial Solutions revenue declined 16.3% to $48.5 million, with product, materials, and service down $6.2 million, $1.9 million, and $1.3 million, respectively. The Geomagic divestiture and weak service bureau/jewelry demand drove the declines, partially offset by growth in aerospace & defense. Industrial gross profit fell 29.3% to $13.0 million, pressured by the divestiture, unfavorable price/mix, and lower volumes.
Management’s forward-looking commentary focuses on the 2025 Restructuring Plan, which expects $8.5 million–$14.5 million in pre-tax charges through Q2 2026, primarily cash-based, to streamline operations and achieve sustainable profitability. The company completed the sale of Geomagic in April 2025 for $119.4 million (gain of $125.7 million) and agreed to sell 3DXpert and Oqton in September 2025 for $3.5 million plus royalties. No specific revenue or margin guidance was provided, but management expects cash, equivalents, and financing to meet anticipated requirements, despite macroeconomic uncertainties. Goodwill impairment risk remains for the Healthcare reporting unit due to stock price declines and strategic shifts, though no impairment was recorded in the current period. The company continues to invest in core R&D while reducing costs through restructuring.
Cash and cash equivalents fell sharply to $95.5M from $171.3M at December 31, 2024, driven by the $78M cash used alongside $92M new debt to repurchase $179.7M of 2026 notes. Total debt decreased to $122.6M (carrying value) from $212.0M, reflecting the extinguishment of most 2026 notes. The company maintains $16.8M in restricted cash required by the 2030 notes indenture. Shareholders' equity improved to $221.1M from $176.2M, aided by a $125.7M gain on the Geomagic divestiture.
Purchase commitments total $17.4M as of September 30, 2025, with $9.0M due within twelve months. The company also has a $0.8M standby letter of credit for a real estate lease. A $5.1M suspended penalty remains under the DDTC settlement, subject to compliance spending. The Volumetric earnout dispute has a $1.8M settlement offer recorded in accrued liabilities, but no lawsuit has been filed.
The company repurchased 8.0M shares for $15.0M in June 2025, concurrent with the debt refinancing. No dividends were paid. Debt activity was dominated by the issuance of $92.0M of 5.875% convertible notes due 2030 and the repurchase of $179.7M of 0% notes due 2026, resulting in a net debt reduction of $89.4M. Capital expenditures were $8.0M (2.9% of sales), down from $10.8M in the prior-year period.
Both segments reported lower revenue and gross profit. Healthcare Solutions revenue fell 22.3% YoY to $42.8M; gross profit dropped to $16.4M (38.3% margin) from $23.3M (42.3% margin). Industrial Solutions revenue declined 16.3% to $48.5M; gross profit fell to $13.0M (26.8% margin) from $18.4M (31.8% margin). Geographically, Americas revenue was $52.2M (57.2% of total), EMEA $32.6M (35.7%), and APAC $6.4M (7.0%). One customer accounted for 11.2% of Q3 2025 revenue.
The company's operating cash flow remained negative and worsened significantly year-over-year, from -$37.1M to -$73.1M, driven by a net loss before redeemable non-controlling interest of $49.4M (vs -$222.1M in prior year) but adjusted for large gains on asset sales and debt extinguishment. The gain on disposition of businesses, property, and equipment of $126.3M was a major non-cash credit, masking underlying operational cash burn.
Capital expenditures moderated to $8.0M from $10.8M, indicating reduced investment in fixed assets. The large investing cash inflow of $108.3M primarily reflects $119.4M in proceeds from asset and business sales, which provided liquidity. Financing activities consumed $98.3M due to $170.0M in debt repayments partially offset by $92.0M in new borrowings, plus $15.0M in share repurchases.
Working capital changes were mixed: accounts receivable decreased $18.3M (favorable) but inventories increased $15.5M (unfavorable). Accrued liabilities and deferred revenue also declined. Overall, cash flow from operations remains weak, and the company relied on asset sales and financing to fund operations and capital returns.